1067 related articles for article (PubMed ID: 30676858)
21. Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
Xu Y; Yan J; Zhou C; Wu L; Wang H; Zhao J; Zhou M; Wang J; Zheng X; Zhang L; Jiang K; Zheng X; Miao Q; Wu S; Zou Z; Lian R; He Y; Chen R; Yang S; Li Y; Chen S; Lin G
Eur J Cancer; 2023 Jul; 188():81-89. PubMed ID: 37201385
[TBL] [Abstract][Full Text] [Related]
22. Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer.
Fan Y; Sun R; Wang Z; Zhang Y; Xiao X; Liu Y; Xin B; Xiong H; Lu D; Ma J
J Cancer Res Clin Oncol; 2023 May; 149(5):1667-1677. PubMed ID: 35583827
[TBL] [Abstract][Full Text] [Related]
23. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T
Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230
[TBL] [Abstract][Full Text] [Related]
24. De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors.
Li JW; Cao SH; Xu JL; Zhong H
Cancer Biol Ther; 2019; 20(9):1183-1186. PubMed ID: 31131689
[TBL] [Abstract][Full Text] [Related]
25. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
26. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
27. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
[TBL] [Abstract][Full Text] [Related]
28. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
[TBL] [Abstract][Full Text] [Related]
30. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
31. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.
Dziadziuszko R; Holm B; Skov BG; Osterlind K; Sellers MV; Franklin WA; Bunn PA; Varella-Garcia M; Hirsch FR
Ann Oncol; 2007 Mar; 18(3):447-52. PubMed ID: 17082511
[TBL] [Abstract][Full Text] [Related]
32. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
33. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
Yamaoka T; Ohba M; Arata S; Ohmori T
J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
[TBL] [Abstract][Full Text] [Related]
34. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
[TBL] [Abstract][Full Text] [Related]
35. High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.
Wang F; Fu S; Shao Q; Zhou YB; Zhang X; Zhang X; Xue C; Lin JG; Huang LX; Zhang L; Zhang WM; Shao JY
J Transl Med; 2013 Apr; 11():90. PubMed ID: 23557218
[TBL] [Abstract][Full Text] [Related]
36. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
Cappuzzo F; Marchetti A; Skokan M; Rossi E; Gajapathy S; Felicioni L; Del Grammastro M; Sciarrotta MG; Buttitta F; Incarbone M; Toschi L; Finocchiaro G; Destro A; Terracciano L; Roncalli M; Alloisio M; Santoro A; Varella-Garcia M
J Clin Oncol; 2009 Apr; 27(10):1667-74. PubMed ID: 19255323
[TBL] [Abstract][Full Text] [Related]
37. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
38. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Westover D; Zugazagoitia J; Cho BC; Lovly CM; Paz-Ares L
Ann Oncol; 2018 Jan; 29(suppl_1):i10-i19. PubMed ID: 29462254
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer.
Mi J; Huang Z; Zhang R; Zeng L; Xu Q; Yang H; Lizaso A; Tong F; Dong X; Yang N; Zhang Y
ESMO Open; 2022 Feb; 7(1):100347. PubMed ID: 34953403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]